ATCC®ウェビナーのお知らせ
（セルベースアッセイに有用なiPS細胞について）

ATCC®（メーカー略称：ACC）では 2020年6月5日に無料のウェビナーを開催しました。ATCC®Webにて、録画版をご覧になれますので、是非ご覧いただき、皆様の今後のご研究にお役立て下さい。

・演題：Expand Your Cell-based Assays With an Unlimited, Biologically Relevant Resource
・演者：Brian Shapiro, Ph.D., Scientific Content Specialist, ATCC
・言語：英語
・開催日：2020年6月5日（金）2：00 am（日本時間）（開催済み）

Abstract:
Toxicology and cancer researchers alike are challenged by the lack of a consistent source of cells with high physiological relevance for their cell-based assays. The source tissue for primary cells comes from a variety of donors, which can introduce interexperimental variability and confound experimental results. Differentiated induced pluripotent stem cell (iPSC)-derived cells fulfill the need for a consistent source of cells and physiological relevance. iPSCs are able to be generated in large cell numbers from a single clone, providing the needed consistency. Further, iPSCs can be differentiated into a variety of desired, functional cell types, affording the necessary biological relevance. Here we provide data demonstrating how differentiated iPSC-derived cells can be incorporated into immunoassays or further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.

Key takeaways:

• Differentiated iPSCs lend the ability to run large toxicity studies and drug screens on highly biologically relevant cells.
• ATCC iPSCs were used as the source for three types of differentiated cells: CD34⁺ progenitors, mesenchymal stem cells (MSCs), and monocytes.
• ATCC R&D scientists have generated in-depth data showing the iPSC-derived cells can be incorporated into immunoassays and further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.

© 2020 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise.